November 16, 2017
FDA: Baxter recalls one lot of injectable amiodarone
Editor's Note
The Food and Drug Administration (FDA) on November 15 announced the recall by Baxter International (Deerfield, Illinois) of one lot of Nexterone (amiodarone HCL) 150 mg/100 mL premixed injection because of the presence of particulate matter.
The particulate matter was identified as polyethylene, the primary constituent of the film and ports used to manufacture the bag in which the Nexterone is packaged.
The recalled lot (number NC109925) was distributed between August 23 and October 2, 2017.
Posted 11/15/2017] AUDIENCE: Pharmacy, Cardiology, Risk Manager ISSUE: Baxter International announced it is voluntarily recalling one lot of Nexterone (amiodarone HCl) 150 mg/100 mL Premixed Injection - distributed between 6/23/2017 and 10/2/2017 in the United States to wholesalers/distributors and healthcare facilities - due to the potential presence of particulate matter.
Free Daily News
- Health systems lean toward established partners for AI adoption
- Immigration raids are driving patients back to telehealth and ERs
- Study: Global access to surgery deemed a crisis, leaves 160 million without care
- Large-scale studies link preoperative cognition to delirium risk, reveal its deadly toll after surgery
- Socioeconomic deprivation linked to lower fitness before surgery, UK study finds
- Perioperative medication decisions need individualized risk-benefit approach
- FDA: National IV saline shortage over after years of strained supply
- FDA announces Class 1 recall for Draeger breathing filters
- Hospital CEO departures surge, boards turn to interim leadership
- Study: Attire shapes patient trust, perceptions
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement